<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04364295</url>
  </required_header>
  <id_info>
    <org_study_id>SS-GR-1902</org_study_id>
    <nct_id>NCT04364295</nct_id>
  </id_info>
  <brief_title>Stronger Together Global Registry</brief_title>
  <official_title>Evaluating Real-World Spine Outcomes for Spinal and Orthobiologics Products From Around the World</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SeaSpine, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>SeaSpine, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A global, prospective, non-randomized, multicenter, observational, post-market, medical
      record review registry evaluating real-world evidence for SeaSpine spinal and orthobiologics
      products.
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">March 20, 2020</start_date>
  <completion_date type="Anticipated">September 2024</completion_date>
  <primary_completion_date type="Anticipated">July 2023</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>24 Months</target_duration>
  <primary_outcome>
    <measure>Evaluation of product failure</measure>
    <time_frame>12 months post-operative</time_frame>
    <description>Product failure is defined as product fracture, loosening, gross migration and/or dissociation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Serious Adverse Events related to the spine, fusion or bone healing, and intraoperative and postoperative unanticipated adverse device effects</measure>
    <time_frame>Intra-operative to 24 months</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Spinal Disease</condition>
  <arm_group>
    <arm_group_label>Implanted with SeaSpine spinal or orthobiologics product</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Spinal Surgery</intervention_name>
    <description>Implanted with SeaSpine spinal or orthobiologic product</description>
    <arm_group_label>Implanted with SeaSpine spinal or orthobiologics product</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Approximately 500 patients whom were previously implanted with SeaSpine spinal and
        orthobiologics products
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have been treated with SeaSpine spinal and/or orthobiologic product(s)

          -  Have obtained preoperative radiographic imaging and patient reported outcome, as part
             of standard of care, prior to receiving the SeaSpine product(s)

          -  Have plans to complete radiographic imaging and patient reported outcomes for at least
             two of scheduled follow up visits, per standard of care

        Exclusion Criteria:

          -  Was not implanted with at least one SeaSpine spinal and/or orthobiologic product
             during operation

          -  Any other condition that the Investigator determines is unacceptable for enrollment
             into this registry
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frank Vizesi, PhD</last_name>
    <role>Study Director</role>
    <affiliation>SeaSpine, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>OrthoNeuro</name>
      <address>
        <city>New Albany</city>
        <state>Ohio</state>
        <zip>43054</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 23, 2020</study_first_submitted>
  <study_first_submitted_qc>April 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 28, 2020</study_first_posted>
  <last_update_submitted>April 24, 2020</last_update_submitted>
  <last_update_submitted_qc>April 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spinal Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

